Tolerability of a modern antihypertensive agent: Candesartan cilexetil

Basic Research in Cardiology

Volumn 93, Issue 2 SUPPL., 1998, Pages 54-58

  Andersson, O K ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adverse effects; Angiotensin antagonist; Angiotensinconverting; Enzyme inhibitors; Hypertension; Reninangiotensin system; Tolerability

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; GLUCOSE; LIPID; LOSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; FATIGUE; FEMALE; GLUCOSE HOMEOSTASIS; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LONG TERM CARE; META ANALYSIS; PROTEINURIA; RECEPTOR BINDING; RESPIRATORY TRACT INFECTION; VERTIGO; VIRUS INFECTION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; HUMANS; LOSARTAN; PRODRUGS; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES;

EID: 0031794786     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s003950050217     Document Type: Article

References (29)

1. Andersson OK, Neldam S (1998) The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin ll antagonists, in comparison with losartan. Blood Pressure 7: 53-59 (Pubitemid 28137527)
2. Bauer JH, Reams GP (1995) The angiotensin II type I receptor antagonists. Anew class of antihypertensive drugs. Arch Intern Med 155: 1361-1368
3. Black DM et al. (1987) for the SHEP Pilot Research Group. Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. J Geront 42: 552-557 (Pubitemid 17141541)
4. Belcher G et al. (1997) Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 11 (Suppl 2): S85-S89 (Pubitemid 27464518)
5. Belz GG et al. (1997) Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 11 (Suppl 2): S45-S47 (Pubitemid 27464507)
6. Coulter DM, Edwards IR (1987) Cough associated with captopril and enalapril. Br Med J Clin Res Ed 294: 1521-3
7. Croog SH et al. (1986) The effects of antihypertensive therapy on the quality of life. N Engl J Med 314: 1657-1664 (Pubitemid 16097842)
8. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials (1995) Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273: 1450-1456
9. Gill TM, Fenstein AR (1994) A critical appraisal of the quality of life measurements. JAMA 272: 619-626 (Pubitemid 24255222)
10. Hedner T et al. (1992) Angioedema in relation to treatment with angiotensin converting enzyme inhibitors. Br Med J 304: 941-945
11. Hjemdahl P, Wiklund IK (1992) Quality of life on antihypertensive drug therapy: scientific end-point or marketing exercise. J Hypertens 10: 1437-1447
12. Hubner R, Högemann AM, Sunzel M, Riddell JG (1997) Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 11 (Suppl 2): S19-S25 (Pubitemid 27464501)
13. Israili ZH, Hall WD (1992) Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Int Med 117: 234-242
14. Jones JK et al. (1995) Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br Med J 11: 293-295
15. Lacourcie're Y et al. (1994) Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 12: 1387-1393
16. Levy D et al. (1996) The progression from hypertension to congestive heart failure. JAMA 275: 1557-1562 (Pubitemid 26154241)
17. Lewis EJ et al. (1993) The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462 (Pubitemid 23335891)
18. Maschio G et al. (1996) Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945 (Pubitemid 26114159)
19. Messerli FH, Weber MA, Brunner HR (1996) Angiotensin II receptor inhibition. A new therapeutic principle. Arch Intern Med 156: 1957-1965 (Pubitemid 26318103)
20. Morice AH et al. (1987) Angiotensin-converting enzyme and the cough reflex. Lancet ii: 1116-1118 (Pubitemid 17154829)
21. Neaton JD et al. (1993) Treatment of mild hypertension study. Final results. JAMA 270: 713-724 (Pubitemid 23226630)
22. Nishikawa K, Naka T, Chatani F, Yoshimura Y(1997) Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 11 (Suppl 2): S9-S17 (Pubitemid 27464500)
23. Ojima M et al. (1997) Candesartan (CV- 11974) dissociates slowly from that angiotensin AT, receptor. Eur J Pharmacol 319: 137-146 (Pubitemid 27051327)
24. O'Kane KPJ, Fridman K, McInnes G (1997) Tolerability and efficacy of candesartan cilexetil 32 mg once daily in hypertensive patients. Am J Hypertens 10 (4Pt2): 111A
25. Ondetti MA, Rubin B, Cushman DW (1977) Design of specific inhibitors of angiotensin converting enzyme:a new class of orally active antihypertensive agents. Science 196: 441-444 (Pubitemid 8073845)
26. Schulman N et al. (1982) Correlates of attendance and compliance in the hypertension detection and follow-up program. Controlled Clin Trials 3: 13-27
27. Testa MA et al. (1993) Quality of life and antihypertensive therapy in men. N Engl Med 328: 907-913
28. Trenkwalder P, Lehtovirta M, Dahl K (1997) Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 11 (Suppl 2): S81-S8 (Pubitemid 27464517)
29. van Lier JJ, van Heiningen PNM, Sunzel M (1997) Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 11 (Suppl 2): S27-S28 (Pubitemid 27464502)